What matters to patients and clinicians when discussing the impact of cancer medicines on health-related quality of life? Consensus-based mixed methods approach in prostate cancer

Tools

Dunlop, Emma and Ferguson, Aimee and Mueller, Tanja and Baillie, Kelly and Clarke, Julie and Laskey, Jennifer and Kurdi, Amanj and Wu, Olivia and Jones, Robert and Glen, Hilary and Bennie, Marion (2022) What matters to patients and clinicians when discussing the impact of cancer medicines on health-related quality of life? Consensus-based mixed methods approach in prostate cancer. Supportive Care in Cancer, 30 (4). pp. 3141-3150. ISSN 1433-7339 (https://doi.org/10.1007/s00520-021-06724-6)

[thumbnail of Dunlop-etal-SCC-2021-What-matters-to-patients-and-clinicians-when-discussing-the-impact-of-cancer-medicines-on-health-related]
Preview
 Text. Filename: Dunlop_etal_SCC_2021_What_matters_to_patients_and_clinicians_when_discussing_the_impact_of_cancer_medicines_on_health_related.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (972kB)| Preview

Abstract

Objective: To identify what matters to clinicians and patients when discussing cancer medicines' impact on health-related quality of life (HRQoL). Methods: A framework of HRQoL domain/domain elements was developed, informed by analysis of published patient reported outcome measures (PROMs), applicable to prostate cancer. Using mixed methods (eDelphi, Nominal Group Technique and questionnaire), prostate cancer clinicians and patients attending prostate cancer clinics and support groups were asked which domains/domain elements would be important to them when discussing the impact prostate cancer medicines have on their HRQoL. Results: Twenty-one clinicians and 71 patients participated from the West of Scotland. Clinicians and patients identified 53/62 domain elements across seven domains as important, of which 32 (60%) were common to both groups. Clinicians placed more importance than patients on Mood & Emotion; in contrast, patients placed importance on a broader range of Symptoms & Side Effects, being informed about their care, and having effective healthcare professional collaboration. Conclusion: This study provides insight into the similarities and differences between what clinicians and patients think is important when discussing the impact of cancer medicines on HRQoL. Future research should involve exploring the potential for consistency of medicines PROMs across different cancer types to support patient-clinician communication and drive improvements in care.

ORCID iDs

Dunlop, Emma ORCID logoORCID: https://orcid.org/0000-0002-0719-7614, Ferguson, Aimee ORCID logoORCID: https://orcid.org/0000-0002-5195-3667, Mueller, Tanja ORCID logoORCID: https://orcid.org/0000-0002-0418-4789, Baillie, Kelly, Clarke, Julie, Laskey, Jennifer, Kurdi, Amanj ORCID logoORCID: https://orcid.org/0000-0001-5036-1988, Wu, Olivia, Jones, Robert, Glen, Hilary and Bennie, Marion ORCID logoORCID: https://orcid.org/0000-0002-4046-629X;
CORE (COnnecting REpositories)